Published in Nat Genet on November 01, 1997
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res (2002) 16.02
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer (2000) 4.37
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet (2000) 2.77
Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet (1999) 2.21
The 2588G-->C mutation in the ABCR gene is a mild frequent founder mutation in the Western European population and allows the classification of ABCR mutations in patients with Stargardt disease. Am J Hum Genet (1999) 2.20
The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. Am J Hum Genet (2000) 1.95
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet (2003) 1.93
BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet (2002) 1.80
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer (2004) 1.77
Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science (2014) 1.74
Copy number variations and cancer. Genome Med (2009) 1.59
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet (2003) 1.58
Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. Am J Hum Genet (2002) 1.55
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J (2010) 1.52
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet (1999) 1.45
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet (2000) 1.34
A mobile threat to genome stability: The impact of non-LTR retrotransposons upon the human genome. Semin Cancer Biol (2010) 1.34
Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer (2007) 1.30
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res (2008) 1.24
Germline DNA copy number variation in familial and early-onset breast cancer. Breast Cancer Res (2012) 1.24
Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families. BMC Med Genet (2007) 1.19
Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer (2000) 1.16
Genomic rearrangements in BRCA1 and BRCA2: A literature review. Genet Mol Biol (2009) 1.14
A novel approach for determining cancer genomic breakpoints in the presence of normal DNA. PLoS One (2007) 1.12
Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res (2011) 1.11
Regulation of double-strand break-induced mammalian homologous recombination by UBL1, a RAD51-interacting protein. Nucleic Acids Res (2000) 1.06
Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot. Am J Hum Genet (2002) 1.05
BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study. Eur J Cancer (2007) 1.01
BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. Fam Cancer (2006) 1.00
Founder populations and their uses for breast cancer genetics. Breast Cancer Res (2000) 0.99
Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico. Cancer Genet (2012) 0.95
Imaging of single DNA molecule: applications to high-resolution genomic studies. Chromosome Res (1999) 0.94
Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet (2005) 0.94
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br J Cancer (1999) 0.93
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. J Med Genet (2001) 0.92
Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br J Cancer (2000) 0.92
High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. J Med Genet (1999) 0.92
MLPAinter for MLPA interpretation: an integrated approach for the analysis, visualisation and data management of Multiplex Ligation-dependent Probe Amplification. BMC Bioinformatics (2010) 0.91
Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. Fam Cancer (2010) 0.88
BRCA1 and BRCA2 mutations in central and southern Italian patients. Breast Cancer Res (2000) 0.88
Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med Genet (2008) 0.87
Mapping genomic deletions down to the base: a quantitative copy number scanning approach used to characterise and clone the breakpoints of a recurrent 7p14.2p15.3 deletion. Hum Genet (2004) 0.87
Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer (2000) 0.87
BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer (2004) 0.87
A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol Biomarkers Prev (2006) 0.86
Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn (2008) 0.86
High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic. BMC Med Genet (2007) 0.84
Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet (2012) 0.84
Identification of a C/G polymorphism in the promoter region of the BRCA1 gene and its use as a marker for rapid detection of promoter deletions. Br J Cancer (1999) 0.83
Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer (2000) 0.83
Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. Fam Cancer (2008) 0.83
Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. Br J Cancer (2001) 0.82
A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. Fam Cancer (2005) 0.81
BRCA1 and BRCA2 germline mutation analysis in the Indonesian population. Breast Cancer Res Treat (2007) 0.81
Detection of exon skipping events in BRCA1 RNA using MLPA kit P002. Mol Biol Rep (2012) 0.79
The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. BMC Med Genet (2006) 0.79
Characterization of an Italian founder mutation in the RING-finger domain of BRCA1. PLoS One (2014) 0.79
Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. Breast Cancer Res (2011) 0.79
A multi-exonic BRCA1 deletion identified in multiple families through single nucleotide polymorphism haplotype pair analysis and gene amplification with widely dispersed primer sets. J Mol Diagn (2005) 0.79
Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants. Hum Mutat (2016) 0.78
Microarray MAPH: accurate array-based detection of relative copy number in genomic DNA. BMC Genomics (2006) 0.78
Overestimation of hereditary breast cancer risk. Ann Surg (1998) 0.78
Identification of rare germline copy number variations over-represented in five human cancer types. Mol Cancer (2015) 0.78
Characterization of Alu and recombination-associated motifs mediating a large homozygous SPG7 gene rearrangement causing hereditary spastic paraplegia. Neurogenetics (2014) 0.77
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features. Br J Cancer (2001) 0.77
The BRCA1 exon 13 duplication in the Swedish population. Fam Cancer (2005) 0.77
The deletion of exons 3-5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families. Fam Cancer (2013) 0.77
A novel pathogenic large germline deletion in adenomatous polyposis coli gene in a Chinese family with familial adenomatous polyposis. Oncotarget (2016) 0.77
Low prevalence of BRCA1 exon rearrangements in familial and young sporadic breast cancer patients. Fam Cancer (2006) 0.76
Reduced expression of APC-1B but not APC-1A by the deletion of promoter 1B is responsible for familial adenomatous polyposis. Sci Rep (2016) 0.76
BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome. Genet Mol Biol (2016) 0.76
Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget (2016) 0.75
Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil. Genet Mol Biol (2016) 0.75
A complex rearrangement in the APC gene uncovered by multiplex ligation-dependent probe amplification. J Mol Diagn (2007) 0.75
The association of copy number variation and percent mammographic density. BMC Res Notes (2015) 0.75
Genomic rearrangement screening of the BRCA1 from seventy Iranian high-risk breast cancer families. J Res Med Sci (2016) 0.75
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum (1991) 9.82
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science (2000) 8.64
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature (1995) 7.11
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell (1996) 5.99
Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region. Cell (1991) 5.84
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer (1999) 5.47
Micrometastases and survival in stage II colorectal cancer. N Engl J Med (1998) 5.11
The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet (1989) 5.09
Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet (1990) 4.99
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet (1993) 4.21
Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology (1997) 3.97
Minor Xp21 chromosome deletion in a male associated with expression of Duchenne muscular dystrophy, chronic granulomatous disease, retinitis pigmentosa, and McLeod syndrome. Am J Hum Genet (1985) 3.83
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet (1989) 3.81
Estimating Y chromosome specific microsatellite mutation frequencies using deep rooting pedigrees. Hum Mol Genet (1997) 3.78
Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet (1995) 3.61
A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem (1993) 3.41
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res (1988) 3.31
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet (1998) 3.28
A deletion hot spot in the Duchenne muscular dystrophy gene. Genomics (1988) 3.18
Prenatal diagnosis and carrier detection of Duchenne muscular dystrophy with closely linked RFLPs. Lancet (1985) 3.08
Isolation of probes detecting restriction fragment length polymorphisms from X chromosome-specific libraries: potential use for diagnosis of Duchenne muscular dystrophy. Hum Genet (1985) 3.08
Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev (1997) 2.96
Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol (1987) 2.96
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet (2000) 2.84
WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet (1998) 2.77
E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer (2006) 2.74
EAA/EMQN best practice guidelines for molecular diagnosis of y-chromosomal microdeletions. State of the art 2004. Int J Androl (2004) 2.70
Array-CGH detection of micro rearrangements in mentally retarded individuals: clinical significance of imbalances present both in affected children and normal parents. J Med Genet (2005) 2.60
Rapid subchromosomal localization of cosmids by nonradioactive in situ hybridization. Cytogenet Cell Genet (1990) 2.60
Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet (1989) 2.44
Direct detection of more than 50% of the Duchenne muscular dystrophy mutations by field inversion gels. Nature (1987) 2.44
A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer (2006) 2.33
Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet (1999) 2.32
In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry (1988) 2.26
E2F-5, a new E2F family member that interacts with p130 in vivo. Mol Cell Biol (1995) 2.26
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol (2001) 2.25
Immunoglobulin containing cells in inflammatory bowel disease of the colon: a morphometric and immunohistochemical study. Gut (1980) 2.24
The PWWP domain: a potential protein-protein interaction domain in nuclear proteins influencing differentiation? FEBS Lett (2000) 2.24
The X chromosome shows less genetic variation at restriction sites than the autosomes. Am J Hum Genet (1986) 2.22
Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med (1998) 2.17
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15
A physical map of 4 million bp around the Duchenne muscular dystrophy gene on the human X-chromosome. Cell (1986) 2.12
Germinal mosaicism increases the recurrence risk for 'new' Duchenne muscular dystrophy mutations. J Med Genet (1989) 2.11
Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci (1992) 2.11
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Protein truncation test (PTT) for rapid detection of translation-terminating mutations. Hum Mol Genet (1993) 2.08
Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet (2012) 2.06
[Genetic research with stored human tissue: a coding procedure with optimal use of information and protection of privacy]. Ned Tijdschr Geneeskd (2004) 2.06
A 10-megabase physical map of human Xp21, including the Duchenne muscular dystrophy gene. Genomics (1988) 2.04
E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer (1997) 2.02
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer (2013) 2.01
A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet (1997) 2.01
Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet (1993) 2.01
TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. Proc Natl Acad Sci U S A (1993) 2.00
Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol (1999) 1.99
Ever since Knudson. Trends Genet (2001) 1.96
Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science (1990) 1.92
Unusual scarcity of restriction site polymorphism in the human thyroglobulin gene. A linkage study suggesting autosomal dominance of a defective thyroglobulin allele. Hum Genet (1984) 1.90
Two subsets of human alphoid repetitive DNA show distinct preferential localization in the pericentric regions of chromosomes 13, 18, and 21. Cytogenet Cell Genet (1986) 1.90
Long-range genomic map of the Duchenne muscular dystrophy (DMD) gene: isolation and use of J66 (DXS268), a distal intragenic marker. Genomics (1987) 1.89
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet (1994) 1.88
Analysis of molecular variance (AMOVA) of Y-chromosome-specific microsatellites in two closely related human populations. Hum Mol Genet (1996) 1.84
The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol (2001) 1.84
The human thyroglobulin gene: a polymorphic marker localized distal to C-MYC on chromosome 8 band q24. Hum Genet (1985) 1.82